Christophe Moreno
Université libre de Bruxelles
281 Papers
1.9K Citations
Christophe Moreno is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Medicine & Hepatitis C. The author has an hindex of 53, co-authored 259 publications. Previous affiliations of Christophe Moreno include Free University of Brussels & University of Toronto.
Chat about Author
Papers
•Journal Article
Prise en charge de l'hépatite C chronique en 2012 en Belgique.
TL;DR: Treatment of chronic hepatitis C has considerably improved and triple therapy represents a major advance, by increasing the possibility of viral eradication, but such therapy also presents new challenges, including the need for strict compliance, risk of additional side effects and development of resistant variants, drug-drug interactions, etc.
1
A two-stage genome-wide association study identifies tm6sf2 and mboat7 as risk loci for alcohol-related cirrhosis
Stephan Buch,Felix Stickel,Eric Trepo,Michael J. Way,A Herrmann,Hans-Dieter Nischalke,Mario Brosch,Jonas Rosendahl,Thomas Berg,Janett Fischer,Monika Ridinger,M. Rietschel,Andrew McQuillin,Josef Frank,Falk Kiefer,Stefan Schreiber,Wolfgang Lieb,Michael Soyka,Christian Datz,Renate Schmelz,Stephan I. Brückner,Norbert Wodarz,Jacques Devière,Nicolas Clumeck,Christoph Sarrazin,Frank Lammert,Thierry Gustot,Pierre Deltenre,H. Völtzke,Markus M. Lerch,Julia Mayerle,Florian Eyer,Clemens Schafmayer,Sven Cichon,M. M. Nöthen,Michael Nothnagel,David Ellinghaus,Annegret Franke,Steffen Zopf,Claus Hellerbrand,Christophe Moreno,Denis Franchimont,Marsha Y. Morgan,Jochen Hampe +43 more
TL;DR: The primary end point was sustained virologic response 12 weeks after treatment (SVR12) and SVR12 rates were highest in those receiving SOF+PEG/RBV for 12 weeks (93%) as compared to SOF+, RBV for 24 weeks (84%, p 0.008) or 16 weeks (71%, p < 0.001).
1
749 Role of the Cirrhosis Risk Score (CRS) for the Prediction of Fibrosis Progression in Hepatitis C Patients with Minimal Liver Disease
Pierre Pradat,Eric Trepo,Andrej Potthoff,Rakesh K. Bakshi,Bradford A. Young,Robert Lagier,Christophe Moreno,Arnaud Lemmers,Thierry Gustot,Christian Trepo,Michael Adler,Heiner Wedemeyer +11 more
1
Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort
Aurélie Barrail-Tran,Lauriane Goldwirt,Thibaut Gelé,Claire Laforest,Audrey Lavenu,Audrey Lavenu,H. Danjou,Sylvie Radenne,Vincent Leroy,Pauline Houssel-Debry,Christophe Duvoux,Nassim Kamar,Victor de Lédinghen,Valérie Canva,Filomena Conti,François Durand,Louis d’Alteroche,Danielle Botta-Fridlund,Christophe Moreno,Carole Cagnot,Didier Samuel,Claire Fougerou-Leurent,Georges-Philippe Pageaux,Jean-Charles Duclos-Vallée,Anne Marie Taburet,Audrey Coilly +25 more
TL;DR: Liver transplant patients with a recurrence of hepatitis C who are initiating ribavirin combined with a sofosbuvir-daclatasvir direct-acting antiviral regimen may be at risk of lower tacrolimus concentrations because of probable ribvirin-induced anaemia and higher fibrosis score, although there are no effects on cyclosporine levels.